US Stock Futures Flat Ahead Of Durable-Goods Orders Data

Loading...
Loading...
Pre-open movers
US stock futures traded mostly flat in early pre-market trade. Data on durable goods orders for February will be released at 8:30 a.m. ET. Futures for the Dow Jones Industrial Average gained 1 point to 17,950.00, while the Standard & Poor's 500 index futures rose 1.15 points to 2,086.15. Futures for the Nasdaq 100 index gained 4.40 points to 4,433.40.
A Peek Into Global Markets
European markets were lower today, with the Spanish Ibex Index dropping 0.38%, STOXX Europe 600 Index falling 0.44% and German DAX 30 index dropping 0.47%. French CAC 40 Index slipped 0.63% and London's FTSE 100 Index fell 0.06%. In Asian markets, Japan's Nikkei Stock Average gained 0.17%, Hong Kong's Hang Seng Index climbed 0.53%, China's Shanghai Composite Index slipped 0.83% and India's BSE Sensex slipped 0.18%.
Broker Recommendation
Analysts at CLSA downgraded
Tesla MotorsTSLA
from Outperform to Underperform. Tesla shares fell 1.84% to $198.00 in pre-market trading.
Breaking news
  • VBL Therapeutics VBLT today announced top-line interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM), which demonstrated a statistically significant improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin(R)) upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone upon disease progression (p=0.05). To read the full news, click here.
  • WABCO WBC signed a long-term supply agreement with Hendrickson Trailer Commercial Vehicle Systems to provide an advanced air disc brake (ADB) system for trailers in North America. To read the full news, click here.
  • Samsung SDI and ABB ABB have signed a memorandum of understanding to establish a strategic commercial alliance. Samsung SDI and ABB join forces to develop and market microgrid systems that comprise energy storage solutions. To read the full news, click here.
  • Avalanche Biotechnologies AAVL today announced that it has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop products based on Avalanche's proprietary Ocular BioFactory™ Platform for the treatment of color vision deficiency (CVD), commonly known as red-green color blindness. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsCLSAUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...